Navigation Links
Surveyed U.S. Neurologists Are More Likely Than Payers to Consider Biogen Idec's Tecfidera to be a Breakthrough in the Treatment of Multiple Sclerosis
Date:9/3/2013

BURLINGTON, Mass., Sept. 3, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that more than half of surveyed neurologists consider Biogen Idec's Tecfidera to be a breakthrough in the treatment of multiple sclerosis (MS), slightly greater than those who feel the same about Novartis's Gilenya and nearly twice as many as for Genzyme's Aubagio. Conversely, less than one-third of surveyed managed care organization (MCO) pharmacy directors/medical directors (PDs/MDs) identify Gilenya, Aubagio or Tecfidera as breakthrough treatments, perhaps underscoring their decision to most commonly cover all three oral agents on nonpreferred tiers in their largest commercial plans. Notably, approximately one-quarter of surveyed MCO PDs/MDs did not cover Aubagio or Tecfidera at the time the survey was fielded, which is likely due to the recent launches of these agents. 

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The U.S. Physician and Payer Forum report entitled The Rapidly Evolving Multiple Sclerosis Treatment Landscape: How Are U.S. Physicians and Payers Responding to the Influx of New Disease-Modifying Therapies?  also finds that two emerging products, Biogen Idec's Plegridy (a pegylated version of Biogen Idec's Avonex) and Teva's Copaxone 40 mg/ml, dosed three-times weekly (a reformulation of Teva's once-daily 20mg/ml Copaxone), will experience usage patterns and market access positioning similar to those of their respective predecessor compounds. This finding suggests that physicians and payers consider the clinical value of these new products to be sufficient to drive use and coverage, but that they lack strong differentiation from their respective
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Up to Sixty Percent of Surveyed U.S. Managed Care Organization Directors Expect to Cover Key Emerging Therapies for Parkinsons Disease on Their Largest Commercial Plan
2. The Majority of Surveyed Oncologists Prescribe Avastin Off-label to Their Ovarian Cancer Patients; However Approximately Half Encounter Access and Reimbursement Hurdles
3. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
4. Surveyed U.S. and European Neurologists Identify Better Seizure-Free Efficacy as One of the Greatest Unmet Needs in Treating Partial-Onset Seizures in Refractory Epilepsy Patients
5. One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs
6. Rising Drug Resistance is Driving Early-Line Use of Powerful Antibiotics Such as Carbapenems for Gram-Negative Infections, According to Surveyed EU5 Physicians
7. For Second- and Subsequent-Line Metastatic Castrate-Resistant Prostate Cancer, Surveyed Oncologists Indicate that Improved Symptom Control and Quality of Life is one of the Greatest Unmet Needs
8. For Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is One of the Greatest Unmet Needs
9. The Majority of Surveyed Gastroenterologists in the EU5 Identify Remicade as Their Most Preferred Biologic for the Treatment of Ulcerative Colitis
10. For Treating Clostridium difficile Infections, Surveyed Infectious Disease Specialists Agree That Effect on Recurrence Rate is One of the Drug Attributes that Most Influences Their Prescribing Decisions
11. Surveyed U.S. Pulmonologists Expect to Treat Nearly 50 Percent of Their Severe, Refractory Asthma Patients With a Biologic or Biosimilar Version of Xolair By the End of 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... December 15, 2014 ... 19. und 20. Februar sind alle akkreditierten ... MEDICINE ECOSYSTEM PARTNER PROGRAMM ™ 2015 in ... Diese Tagung soll dazu beitragen, ... geben, die neue profitablen Unternehmensdienstleistungen, die für ...
(Date:12/15/2014)... Research and Markets , ... has announced the addition of the "Cardiac Guidewires ... their offering. Global Guidewires sector is projected to ... America accounts for nearly 35% (2015) of ... claims approximately 25% (2018). Asia-Pacific ...
(Date:12/15/2014)... and BRIDGEWATER, N.J. , Dec. ... and Sanofi US (EURONEXT: SAN and NYSE: SNY) are ... to launch Cholesterol Counts , an awareness program ... their numbers, and the risks associated with high LDL-C ... www. CholesterolCounts .com to take a brief poll ...
Breaking Medicine Technology:Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 2Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 3Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 5Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 6
... 2012  Genalyte, Inc., a life sciences company developing ... completion of an $11.8 million Series B financing.  ... and private investors from Genalyte,s Series A round ... to use the new funds primarily for commercialization ...
... ThermoGenesis Corp. (NASDAQ: KOOL ), a ... and store adult stem cells, said today that its ... first company in China to receive accreditation from the ... is an international, not-for-profit association representing nearly 2,000 institutions ...
Cached Medicine Technology:Genalyte, Inc. Completes $12 Million Series B Financing to Commercialize Its Maverick™ Next-Generation Multiplexing Platform 2Genalyte, Inc. Completes $12 Million Series B Financing to Commercialize Its Maverick™ Next-Generation Multiplexing Platform 3ThermoGenesis Announces AABB Accreditation for Cord Blood Products Customer in China 2ThermoGenesis Announces AABB Accreditation for Cord Blood Products Customer in China 3
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... efficient to use the drug cetuximab only in colorectal cancer ... a study published online August 7 in the Journal ... tumors harbored wild-type KRAS were found to have a higher ... by the National Cancer Institute of Canada Clinical Trials Group. ...
... Provides Protection for People with Lupus and other Chronic Diseases ... Lupus Foundation of America (LFA) President and Chief Executive Officer, Sandra ... Access to Prescription Medications Act of 2009" introduced on Thursday, ... , , "We support and ...
... , , MORRISTOWN, N.J., Aug. 7 ... specialty pharmaceutical company, announced today that one lot of 100 mcg/hr ... voluntarily recalled from wholesalers and pharmacies. The recalled patches are ... were manufactured by Watson Laboratories, Inc. and distributed by Watson Pharma, ...
... , NEW YORK, Aug. 7 Duane ... Reade Inc. and Duane Reade (collectively, the "Issuers"), had closed ... Secured Notes due August 1, 2015 (the "Notes"). The ... The Notes were priced at 97.417%, representing a yield to ...
... time for decisions, , FRIDAY, Aug. 7 (HealthDay News) -- ... serious complications for themselves and their moms. , Among single-baby ... "breech presentations," with the baby,s bottom, rather than head, positioned ... numbers are small, experts say the risks can be big. ...
... keep new beta cells under control , FRIDAY, Aug. 7 ... that plays a key role in the conversion of pancreas ... to a new treatment for type 1 diabetes. , In ... called Pax4 is turned on in pancreatic cells, the cells ...
Cached Medicine News:Health News:Cost-effectiveness of cetuximab in metastatic colorectal cancer 2Health News:The Lupus Foundation of America Applauds New Legislation that Caps Out-of-Pocket Drug Costs 2Health News:Watson Announces Limited Recall Of Fentanyl Transdermal System 2Health News:Watson Announces Limited Recall Of Fentanyl Transdermal System 3Health News:Duane Reade Holdings, Inc. Announces Closing of Offering of $300 Million of 11.75% Senior Secured Notes Due 2015 2Health News:Duane Reade Holdings, Inc. Announces Closing of Offering of $300 Million of 11.75% Senior Secured Notes Due 2015 3Health News:If Baby Is Breech, Technology Might Help 2Health News:If Baby Is Breech, Technology Might Help 3
Inquire...
Inquire...
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Medicine Products: